Workflow
KEYUAN PHARMA(301281)
icon
Search documents
科源制药:关于股票交易异常波动及严重异常波动的公告
2023-08-11 13:24
证券代码:301281 证券简称:科源制药 公告编号:2023-027 山东科源制药股份有限公司 关于股票交易异常波动及严重异常波动的公告 4、公司拟于2023年8月22日披露《2023年半年度报告》。截至本公告披露日, 公司2023年半年度报告相关工作正在有序筹备中,未向任何第三方提供2023年半 年度财务数据,亦不存在需披露业绩预告或业绩快报的情形。 5、公司郑重提醒广大投资者:公司指定的信息披露媒体为《证券时报》《上 海证券报》《中国证券报》《证券日报》和巨潮资讯网(www.cninfo.com.cn), 有关本公司的信息均以在上述指定媒体刊载的公告为准,敬请广大投资者理性投 资,注意投资风险。 一、股票交易异常波动及严重异常波动的具体情况 公司股票交易于2023年8月10日、2023年8月11日连续二个交易日收盘价格涨 幅偏离值累计超过 30%,根据《深圳证券交易所交易规则》的相关规定,属于股 票交易异常波动的情形。 同时,公司股票交易连续五个交易日(2023年8月7日至2023年8月11日)收 盘价格涨幅偏离值累计超过 100%,根据《深圳证券交易所交易规则》的相关规 定,属于股票交易严重异常波动的 ...
科源制药:关于股票交易异常波动的公告
2023-08-09 08:50
证券代码:301281 证券简称:科源制药 公告编号:2023-026 山东科源制药股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 一、 股票交易异常波动情况 山东科源制药股份有限公司(以下简称"公司")连续两个交易日(2023 年8月8日、8月9日)收盘价格涨幅偏离值累计超过30%,根据《深圳证券交易所 交易规则》的有关规定,属于股票交易异常波动的情况。 二、 公司关注并核实的情况说明 5、经核查,公司控股股东、实际控制人在公司本次股票交易异常波动期间 不存在买卖公司股票的情况。 6、公司不存在违反信息公平披露的其他情形。 三、 关于不存在应披露而未披露信息的说明 本公司董事会确认,本公司目前没有任何根据《深圳证券交易所创业板股票 上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等;董事会也未获悉本公司有根据《深圳证券交易所创业板股票上市 规则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格 产生较大影响的信息;公司前期披露的信息不存在需要更正、补充之处。 四、风 ...
科源制药:关于举行2022年度网上业绩说明会的公告
2023-05-08 11:18
为充分尊重投资者、提升交流的针对性,现就公司2022年度业绩说明会提前 向投资者公开征集问题,广泛听取投资者的意见和建议。投资者可于2023年5月 17日(星期三)15:00前访问https://ir.p5w.net/zj/,或扫描下方二维码,进 入问题征集专题页面。公司将在2022年度业绩说明会上,对投资者普遍关注的问 题进行回答。 欢迎广大投资者积极参与本次网上说明会。 (问题征集专题页面二维码,扫码自动匹配移动端) 证券代码:301281 证券简称:科源制药 公告编号:2023-021 山东科源制药股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司(以下简称"公司")定于2023年5月17日(星 期三)15:00-16:30在全景网举办2022年度业绩说明会,本次年度业绩说明会将 采用网络远程的方式举行,投资者可登陆全景网"投资者关系互动平台" (https://ir.p5w.net)参与本次年度业绩说明会。 出席本次说明会的人员有:公司董事长伦立军先生、董事会秘书李春桦先 ...
科源制药(301281) - 2022 Q4 - 年度财报
2023-04-25 16:00
Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in 2022 [19]. - The company's operating revenue for 2022 was CNY 442,865,098.55, representing a 5.22% increase compared to CNY 420,888,625.75 in 2021 [24]. - The net profit attributable to shareholders for 2022 was CNY 91,278,406.78, a 16.77% increase from CNY 78,172,475.70 in 2021 [24]. - The company achieved a significant increase in net profit, with retained earnings rising to CNY 224,213,729.26, up from CNY 140,274,729.92, marking a 9.33% increase in proportion [96]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a growth of 20% compared to the previous year [141]. - The company reported a total revenue of 1.5 billion RMB for the year 2022, representing a year-on-year growth of 15% [188]. - The net profit for 2022 was 300 million RMB, which is a 15% increase compared to the previous year [152]. Dividend Distribution - The company plans to distribute a cash dividend of 4 RMB per 10 shares to all shareholders, based on a total of 77,350,000 shares [4]. - The company plans to distribute a cash dividend of 4 yuan per 10 shares (including tax), totaling 30,940,000 yuan, which represents 100% of the profit distribution [166]. - A cash dividend of 0.5 RMB per share is proposed, reflecting a payout ratio of 30% of net income [193]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits for the upcoming fiscal year [190]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, including partnerships and collaborations with other firms [19]. - The company is expanding its market presence in Southeast Asia, with plans to enter two new countries by the end of 2023 [141]. - Market expansion plans include entering two new provinces, targeting a 25% increase in market share [149]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential deals [149]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose [189]. - A strategic acquisition of a local competitor was completed, which is expected to enhance market share by 5% in the next fiscal year [141]. Research and Development - The company is investing in research and development to enhance its product offerings and maintain competitive advantage [19]. - The company has invested 100 million RMB in research and development, focusing on innovative drug formulations and delivery systems [141]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency [149]. - Research and development investments were increased, focusing on key projects to enhance product competitiveness [74]. - The company aims to enrich its product line in the anti-inflammatory and diabetes treatment sectors through ongoing R&D efforts, with several projects already submitted for regulatory approval [87]. - The number of R&D personnel increased by 28.57% to 36 in 2022, with a higher proportion of staff holding master's degrees, which rose by 40% [88]. Product Development and Offerings - The company is focusing on expanding its product line, particularly in the cosmetics sector, with new intermediate products like OR10127 and OR10154 [16]. - The company is currently in the process of developing new products, including Dapagliflozin and Furosemide, with ongoing pilot studies and process validations [55]. - The company has made progress in the research and development of several key products, including the quality enhancement of Glimepiride and the process development of Isosorbide Mononitrate [55]. - The company reported that the main products contributing over 10% of revenue include Glimepiride, Metformin Hydrochloride, and Isosorbide Mononitrate, with Glimepiride being a significant oral hypoglycemic agent [53]. Operational Efficiency - The company has achieved a gross profit margin of 30% for the year, reflecting improved operational efficiency [19]. - The gross profit margin improved to 45%, up from 40% in the previous year, indicating better cost management and pricing strategies [141]. - The company implemented a "Four Reductions and Four Enhancements" strategy to improve operational efficiency and cost control [74]. - The company aims to improve operational efficiency by implementing new management strategies, targeting a 15% reduction in operational costs [152]. Risk Management - The company has outlined potential risks in its future operations and has proposed measures to mitigate these risks [4]. - The company faces risks from potential price declines in raw materials due to national drug procurement policies, which could adversely affect profitability [111]. - The company is at risk of not passing consistency evaluations and winning national procurement bids for major formulations, which could impact sales and pricing [115]. - The company is exposed to foreign exchange risks due to some export products being settled in foreign currencies, which may adversely affect performance [115]. Environmental Compliance - The company is committed to enhancing the proportion of green process production in the raw material pharmaceutical industry by 2025 [174]. - The company reported a total pollutant discharge of 33.04 tons per year, with no exceedance of discharge standards [175]. - The company has implemented measures to comply with environmental protection policies and industry standards [174]. - The company has established multiple environmental management systems to ensure compliance with national environmental protection policies and regulations [182]. Corporate Governance - The company has a clear governance structure with independent directors and management personnel [134]. - The company has established independent organizational structures, including a shareholders' meeting, board of directors, and supervisory board, which operate independently from shareholders [129]. - The company has no significant related party transactions that are unfair [130]. - The company has established a comprehensive investor rights protection system [182].
科源制药(301281) - 2023 Q1 - 季度财报
2023-04-25 16:00
Financial Performance - The company's revenue for Q1 2023 was CNY 124,226,061.67, representing a 9.52% increase compared to CNY 113,428,452.99 in the same period last year[5] - Net profit attributable to shareholders was CNY 32,088,662.63, up 16.91% from CNY 27,447,995.23 year-on-year[5] - Total operating revenue for Q1 2023 reached CNY 124,226,061.67, an increase of 9.3% compared to CNY 113,428,452.99 in Q1 2022[19] - Net profit for Q1 2023 was CNY 32,088,662.63, representing a 16.0% increase from CNY 27,447,995.23 in the same period last year[20] - Earnings per share (EPS) for Q1 2023 was CNY 0.55, compared to CNY 0.47 in Q1 2022, indicating a growth of 17.0%[21] Cash Flow - The net cash flow from operating activities increased by 8.66% to CNY 14,153,258.65, compared to CNY 13,025,272.93 in Q1 2022[5] - Cash inflow from operating activities totaled CNY 100,238,318.64, significantly higher than CNY 76,634,292.36 in Q1 2022, marking an increase of 30.8%[23] - The net cash flow from operating activities for Q1 2023 was CNY 14,153,258.65, an increase from CNY 13,025,272.93 in Q1 2022[24] - Cash inflow from financing activities reached CNY 783,366,482.86, with a significant increase due to CNY 782,943,530.00 from investment absorption[24] - The net cash flow from financing activities was CNY 782,755,517.13, a substantial improvement from a net outflow of CNY 289,018.87 in Q1 2022[24] - The total cash and cash equivalents at the end of Q1 2023 stood at CNY 932,397,769.05, up from CNY 70,331,727.17 at the end of Q1 2022[24] - The net increase in cash and cash equivalents for the quarter was CNY 783,423,545.31, compared to CNY 4,982,869.43 in the same period last year[24] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 1,446,370,989.83, a significant increase of 121.91% from CNY 651,789,219.99 at the end of the previous year[5] - Current assets increased to CNY 1,083,076,504.11 from CNY 282,267,007.37, reflecting a substantial rise in liquidity[17] - The total liabilities decreased slightly to CNY 129,206,942.92 from CNY 132,061,203.18, a reduction of 2.1%[20] - The total equity attributable to shareholders rose by 153.43% to CNY 1,317,164,046.91 from CNY 519,728,016.81 at the end of the previous year[5] - The company is focusing on enhancing its financial position and operational efficiency as indicated by the changes in asset and liability structures[16] Expenses - Total operating costs amounted to CNY 89,130,543.28, up from CNY 82,896,009.48, reflecting a year-over-year increase of 7.5%[19] - Research and development expenses increased by 76.56% to CNY 8,110,172.85, compared to CNY 4,593,419.18 in Q1 2022, indicating a focus on innovation[10] - The company experienced a 197.31% increase in sales expenses, totaling CNY 14,413,879.74, primarily due to increased promotional activities[10] - Sales expenses increased to CNY 14,413,879.74 from CNY 4,848,066.82, a rise of 197.5% year-over-year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,244, reflecting a growing investor interest[12] - The total equity attributable to shareholders of the parent company increased to CNY 1,317,164,046.91 from CNY 519,728,016.81, a growth of 153.5%[20] Other Information - The first quarter report was not audited[25]
科源制药:首次公开发行股票并在创业板上市之上市公告书
2023-04-02 12:36
股票简称:科源制药 股票代码:301281 山东科源制药股份有限公司 Shandong Keyuan Pharmaceutical Co.,Ltd. (山东济南市山东商河经济开发区科源街) 首次公开发行股票并在创业板上市 之 上市公告书 保荐人(主承销商) (北京市朝阳区安立路 66 号 4 号楼) 二零二三年四月 特别提示 山东科源制药股份有限公司(以下简称"公司""发行人"或"科源制 药")股票将于 2023 年 4 月 4 日在深圳证券交易所上市。 创业板公司具有业绩不稳定、经营风险高、退市风险大等特点,投资者面 临较大的市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露 的风险因素,审慎做出投资决定。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素,在 新股上市初期切忌盲目跟风"炒新",应当审慎决策、理性投资。 如无特别说明,本上市公告书中的简称或名词的释义与《山东科源制药股 份有限公司首次公开发行股票并在创业板上市招股说明书》(以下简称"招股 说明书")中的相同。 1 第一节 重要声明与提示 一、 重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真 实 ...
科源制药:首次公开发行股票并在创业板上市招股说明书
2023-03-29 23:14
山东科源制药股份有限公司 首次公开发行股票并在创业板上市招股说明书 创业板风险提示:本次发行股票拟在创业板上市,创业板公司具有创新投入大、新旧产 业融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点, 投资者面临较大的市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露 的风险因素,审慎作出投资决定。 山东科源制药股份有限公司 Shandong Keyuan Pharmaceutical Co.,Ltd. (住所:山东济南市山东商河经济开发区科源街) 首次公开发行股票并在创业板上市 招股说明书 者应当以正式公告的招股说明书全文作为投资决定的依据。 保荐机构(主承销商) 1-1-1 (注册稿) (住所:北京市朝阳区安立路 66 号 4 号楼) 免责声明:本公司的发行申请尚未经深圳证券交易所及中国证监会履行相应的程序。 本招股说明书(申报稿)不具有据以发行股票的法律效力,仅供预先披露之用。投资 山东科源制药股份有限公司 首次公开发行股票并在创业板上市招股说明书 发行概况 | 发行股票类型 | 人民币普通股(A股) | | --- | --- | | 发行股数 | 本次公开发行股票1, ...
科源制药:首次公开发行股票并在创业板上市发行结果公告
2023-03-29 20:28
山东科源制药股份有限公司 首次公开发行股票并在创业板上市发行结果公告 保荐人(主承销商):中信建投证券股份有限公司 特别提示 山东科源制药股份有限公司(以下简称"科源制药"或"发行人")首次公 开发行1,935.00万股人民币普通股(A股)并在创业板上市(以下简称"本次发 行")的申请已经深圳证券交易所(以下简称"深交所")创业板上市委员会审议 通过,并已获中国证券监督管理委员会同意注册(证监许可[2023]362号)。发行 人股票简称为"科源制药",股票代码为"301281"。 发行人与本次发行的保荐人(主承销商)中信建投证券股份有限公司(以下 简称"中信建投证券"或"保荐人(主承销商)")协商确定本次发行价格为人 民币44.18元/股,本次发行股份数量为1,935.00万股。 本次发行价格未超过剔除最高报价后网下投资者报价的中位数和加权平均 数,剔除最高报价后通过公开募集方式设立的证券投资基金、全国社会保障基金、 基本养老保险基金、企业年金基金和职业年金基金、符合《保险资金运用管理办 法》等规定的保险资金和合格境外投资者资金报价中位数和加权平均数孰低值, 故保荐人相关子公司无需参与本次战略配售。初始战略配 ...
科源制药:首次公开发行股票并在创业板上市发行公告
2023-03-22 12:38
山东科源制药股份有限公司 首次公开发行股票并在创业板上市发行公告 保荐人(主承销商):中信建投证券股份有限公司 特别提示 山东科源制药股份有限公司(以下简称"科源制药"、"发行人"或"公司") 根据《证券发行与承销管理办法》(证监会令[第208号])(以下简称"《管理办法》")、 《首次公开发行股票注册管理办法》(证监会令[第 205 号])、《深圳证券交易所首 次公开发行证券发行与承销业务实施细则》(深证上[2023]100 号)(以下简称"《业 务实施细则》")、《深圳市场首次公开发行股票网上发行实施细则》(深证上 [2018]279 号)(以下简称"《网上发行实施细则》")、《深圳市场首次公开发行股票 网下发行实施细则(2023 年修订)》(深证上[2023]110 号)(以下简称"《网下发行 实施细则》")、《首次公开发行证券承销业务规则》(中证协发[2023]18 号)、《首次 公开发行证券网下投资者管理规则》(中证协发[2023]19 号)(以下简称"《首发网 下投资者管理规则》")等相关法律法规、监管规定及自律规则等文件,以及深圳 证券交易所(以下简称"深交所")有关股票发行上市规则和最新操作指 ...
科源制药:首次公开发行股票并在创业板上市招股意向书
2023-03-16 13:14
山东科源制药股份有限公司 首次公开发行股票并在创业板上市招股意向书 创业板风险提示:本次发行股票拟在创业板上市,创业板公司具有创新投入大、新旧产 业融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点, 投资者面临较大的市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露 的风险因素,审慎作出投资决定。 山东科源制药股份有限公司 Shandong Keyuan Pharmaceutical Co.,Ltd. (住所:山东济南市山东商河经济开发区科源街) 者应当以正式公告的招股意向书全文作为投资决定的依据。 保荐机构(主承销商) 1-1-1 (注册稿) (住所:北京市朝阳区安立路 66 号 4 号楼) 免责声明:本公司的发行申请尚未经深圳证券交易所及中国证监会履行相应的程序。 本招股意向书(申报稿)不具有据以发行股票的法律效力,仅供预先披露之用。投资 山东科源制药股份有限公司 首次公开发行股票并在创业板上市招股意向书 首次公开发行股票并在创业板上市 招股意向书 发行概况 | 发行股票类型 | 人民币普通股(A股) | | --- | --- | | 发行股数 | 本次公开发行股票1, ...